Syndax Pharmaceuticals, Inc.
SNDX
$19.84
$0.763.98%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 91.76% | 223.64% | 794.90% | 266.97% | 984.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 91.76% | 223.64% | 794.90% | 266.97% | 984.51% |
| Cost of Revenue | 12.18% | -1.67% | 22.59% | -17.74% | 30.52% |
| Gross Profit | 106.04% | 107.97% | 78.49% | 78.61% | 43.42% |
| SG&A Expenses | -5.17% | -8.39% | 32.47% | 44.40% | 50.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.10% | -4.33% | 26.17% | 1.20% | 38.08% |
| Operating Income | 42.33% | 59.04% | 35.09% | 35.89% | 6.55% |
| Income Before Tax | 31.29% | 49.71% | 27.77% | 27.83% | -5.56% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 31.29% | 49.71% | 27.77% | 27.83% | -5.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.29% | 49.71% | 27.77% | 27.83% | -5.56% |
| EBIT | 42.33% | 59.04% | 35.09% | 35.89% | 6.55% |
| EBITDA | 42.34% | 59.05% | 35.10% | 35.89% | 6.55% |
| EPS Basic | 33.35% | 50.89% | 29.07% | 28.82% | -4.26% |
| Normalized Basic EPS | 33.34% | 50.89% | 29.07% | 28.81% | -4.25% |
| EPS Diluted | 33.35% | 50.89% | 29.07% | 28.82% | -4.03% |
| Normalized Diluted EPS | 33.34% | 50.89% | 29.07% | 28.81% | -4.25% |
| Average Basic Shares Outstanding | 3.07% | 2.42% | 1.83% | 1.39% | 1.25% |
| Average Diluted Shares Outstanding | 3.07% | 2.42% | 1.83% | 1.39% | 1.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |